Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT1080222652
JPRN-jRCT1080222652UnknownPhase 4

Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritis

ippon Kayaku Co., Ltd.0 sitesStarted: November 13, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •(1) Patients who have completed final observation after 54-week administration in the phase I/II clinical study and whose symptoms are stable.
  • •(2) Patients for whom administration of CT-P13 is deemed appropriate as of the end of final observation after 54-week administration in the phase I/II clinical study.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
ippon Kayaku Co., Ltd.

Similar Trials

Unknown
Phase 1
Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritisRheumatoid arthritis
JPRN-jRCT2080222369ippon Kayaku Co., Ltd.
Recruiting
Phase 1
ong-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102Fanconi anemia subtype A (FA-A)MedDRA version: 20.0Level: LLTClassification code: 10055206Term: Fanconi's anemia Class: 10010331
CTIS2022-501082-52-00Rocket Pharmaceuticals Inc.14
Active, not recruiting
Phase 1
A study to test how well patients with plaque psoriasis tolerate BI 730357 over a longer period and how effective it isPlaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858
EUCTR2018-003487-31-DEBoehringer Ingelheim Pharma GmbH & Co. KG180
Active, not recruiting
Phase 1
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856
EUCTR2017-003284-35-PLABIVAX30
Active, not recruiting
Phase 1
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856
EUCTR2017-003284-35-HUABIVAX30